Fulminant hepatitis B following rituximab therapy in a patient with Evans syndrome and large B-cell lymphoma.
Bülent
B
Ozgönenel
Dilip
D
Moonka
Süreyya
S
Savaşan
D000328:Adult; D000745:Anemia, Hemolytic, Congenital / Q000150:complications* / Q000188:drug therapy; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D017809:Fatal Outcome; D006509:Hepatitis B / Q000139:chemically induced*; D006801:Humans; D017114:Liver Failure, Acute / Q000139:chemically induced*; D016393:Lymphoma, B-Cell / Q000150:complications* / Q000188:drug therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000150:complications* / Q000188:drug therapy; D008297:Male; D000069283:Rituximab; D013577:Syndrome; D013921:Thrombocytopenia / Q000150:complications* / Q000151:congenital / Q000188:drug therapy; D014775:Virus Activation / Q000187:drug effects
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab